Loading...
NPI 1396408829 · Fort Myers, FL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Neogenomics Laboratories Inc is a clinical medical laboratory provider located in Fort Myers, Florida. This profile covers 66 Medicare and 28 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Neogenomics Laboratories Inc |
| Address | 9490 Neogenomics Way |
| City | Fort Myers |
| State | FL |
| ZIP | 33912 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | October 21, 2021 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $20.9M |
| Medicaid | $2.3M |
This provider is Medicare-dominant in scale: reported lifetime Medicare revenue is $20.9M versus $2.3M in Medicaid, indicating the bulk of billed services and reimbursement comes from Medicare rather than Medicaid. Analysts should treat Medicare performance as the primary lens for assessing this entity’s business impact and network leverage.
Revenue is highly concentrated into a small set of high-value and high-volume services. The precomputed metric shows the top 3 Medicare codes by revenue account for 62.9% of total Medicare revenue, driven principally by 81455 (28.8%) and 88374 (26.1%), while the top 3 Medicaid codes account for 74.2% of total Medicaid revenue, led by 88374 (44.8%) and 88185 (25.6%). This concentration implies that financial performance is sensitive to utilization and reimbursement changes for a very limited set of test types.
The code mix indicates a specialized molecular oncology and hematopathology operation: large shares come from genomic sequencing panels (81455 and 81450) and high-volume slide-based testing such as multiplex in situ hybridization (88374) and immunohistochemistry (88341, 88342, 88360, 88361). Substantial activity in flow cytometry add-on and interpretation codes (88185, 88184, 88189) and cytogenetics (88237, 88264) further supports a high-throughput lab model focused on cancer diagnostics and referral-based specimen processing.
Several individual codes mark this provider as a national-scale outlier for specific services. On Medicare, 88374 ranks #1 of 378 nationally (100th percentile; extreme outlier) with 34.4K claims and $5M revenue, and 88341 and multiple other pathology/immunostain codes rank at or near the top of national lists (for example 88341 is #4 of 10274, 100th percentile; extreme outlier). At the same time 81455 is #2 of 36 nationally (97th percentile) but is labeled here as a typical, unremarkable volume for that code despite its material revenue contribution, indicating heterogeneous national competitive context across different genomic tests.
State-level Medicaid positioning is mixed: 88374 is a large share of Medicaid revenue (44.8%) but ranks only #2 of 3 in-state (50th percentile; typical), whereas flow cytometry and several molecular assays show strong statewide positioning. For example, 88185 ranks #2 of 25 in-state (96th percentile; notably above typical state volume) and 81279 and 81206 rank #1 among in-state peers (100th percentile; notably above typical state volume), indicating the provider is a leading in-state source for select molecular/cytogenetic tests but not uniformly dominant across all high-revenue codes.
Operational scale is evident from very high claim volumes at low per-claim reimbursements for certain service lines, consistent with a high-throughput slide- and marker-processing model. Medicare claim counts such as 64.6K claims for 88185 ($19 avg paid/claim, $1.2M revenue) and 34.4K claims for 88374 ($146 avg paid/claim, $5M revenue) show heavy specimen throughput and automation-supported enumeration workflows rather than exclusively bespoke, low-volume testing.
Despite a relatively recent NPI enumeration date (2021-10-21, ~5 years ago), the provider has achieved rapid volume in specialized services. The combination of national extreme-outlier ranks on several codes and substantial Medicare revenue suggests rapid scale-up in molecular oncology and pathology testing lines since enumeration.
For payer contracting and utilization oversight, the blend of a few high-revenue genomic panels (81455, 81450) and extremely high-volume slide-based services (88374, immunostain codes, and flow cytometry add-ons) identifies priority areas for reimbursement negotiation and capacity assessment. Given the precomputed concentration metrics (top 3 Medicare codes = 62.9% of Medicare revenue; top 3 Medicaid codes = 74.2% of Medicaid revenue) payers should focus analytic and operational review on those specific codes to understand referral patterns, turnaround capacity, and appropriate bundling or price arrangements.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
66 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81455 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen, such as tumor tissue or bone marrow, for DNA and possibly RNA alterations in 51 or more genes known to… | 1,940 | $2,850 | $5.5M |
| 88374 | The lab analyst applies a single multiplex in situ hybridization probe stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. The lab analyst processes the slides… | 34,390 | $150 | $5M |
| 81450 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen, such as blood or bone marrow, for DNA and possibly RNA alterations in five to 50 genes known to impact… | 2,050 | $740 | $1.5M |
| 88185 | The lab analyst performs the technical component of a flow cytometry procedure using cell surface, cytoplasmic, or nuclear markers to characterize cells and aid clinicians in diagnosing patients with… | 64,610 | $20 | $1.2M |
| 81206 | The lab analyst performs the technical lab test to evaluate the major breakpoint gene sequence BCR/ALB1 that occurs on chromosome 22 due to translocation, which involves breakage and reforming of an… | 4,930 | $160 | $789.4K |
| 88341 | The lab analyst applies an additional single antibody stain on a slide or slides prepared from the same patient specimen as the initial antibody stain, such as tumor tissue. Then a qualified… | 15,840 | $40 | $696.8K |
| 88237 | The lab analyst performs a procedure to grow a culture of cells from bone marrow or blood in a neoplastic disorder. | 3,790 | $140 | $531K |
| 81279 | The lab analyst performs the technical lab test on a specimen such as blood to analyze specific gene sequences of the JAK2 (Janus kinase 2) gene, such as exons 12 and 13, which may be associated with… | 1,840 | $180 | $332.1K |
| 88342 | The lab analyst applies an initial single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist,… | 6,330 | $50 | $297.5K |
| 81339 | The lab analyst performs the technical lab test on a specimen such as blood to analyze specific gene sequences of the MPL (MPL proto–oncogene, thrombopoietin receptor) gene, such as exon 10, which… | 1,570 | $180 | $284.4K |
Showing 1–10 of 66
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 66 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
66 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81455 | 1 | 10 | 80 | $2,860 | $2M |
| 81450 | 1 | 10 | 20 | $740 | $322.2K |
| 88374 | 1 | 30 | 130 | $160 | $278.1K |
| 81314 | 3 | 10 | 980 | $320 | $263.3K |
| 88185 | 1 | 20 | 4,720 | $20 | $222.5K |
| 81311 | 15 | 20 | 270 | $290 | $213K |
| 81456 | 2 | 10 | 20 | $2,850 | $199.3K |
| 81218 | 8 | 10 | 250 | $240 | $194.8K |
| 81194 | 3 | 10 | 80 | $510 | $184.5K |
| 88237 | 1 | 10 | 140 | $140 | $175.8K |
Showing 1–10 of 66
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
28 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 88374 | The lab analyst applies a single multiplex in situ hybridization probe stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. The lab analyst processes the slides… | 7,070 | $150 | $1M |
| 88185 | The lab analyst performs the technical component of a flow cytometry procedure using cell surface, cytoplasmic, or nuclear markers to characterize cells and aid clinicians in diagnosing patients with… | 5,720 | $100 | $594.9K |
| 88237 | The lab analyst performs a procedure to grow a culture of cells from bone marrow or blood in a neoplastic disorder. | 2,520 | $40 | $88.1K |
| 88184 | The lab analyst performs the technical component of a flow cytometry procedure using a cell surface, cytoplasmic, or nuclear marker to characterize cells and aid clinicians in diagnosing patients… | 5,030 | $10 | $70.3K |
| 88361 | The lab analyst applies a single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. The lab analyst processes the slides using computer assisted… | 1,260 | $50 | $64.1K |
| 88341 | The lab analyst applies an additional single antibody stain on a slide or slides prepared from the same patient specimen as the initial antibody stain, such as tumor tissue. Then a qualified… | 1,230 | $50 | $61.5K |
| 88360 | The lab analyst applies a single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist, evaluates the… | 3,140 | $20 | $59.7K |
| 88377 | The lab analyst applies a single multiplex in situ hybridization probe stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a… | 1,030 | $50 | $49.3K |
| 88189 | The clinician, typically a pathologist, interprets flow cytometry results of 16 or more markers. | 2,260 | $20 | $45.2K |
| 88342 | The lab analyst applies an initial single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist,… | 2,810 | $10 | $39.3K |
Showing 1–10 of 28
How this provider's Medicaid billing volume and revenue compare to other Florida providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Florida median
28 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 88374 | The lab analyst applies a single multiplex in situ hybridization probe stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. The lab analyst processes the slides… | 2 | 10 | 7,070 | $110 | $956.3K |
| 88185 | The lab analyst performs the technical component of a flow cytometry procedure using cell surface, cytoplasmic, or nuclear markers to characterize cells and aid clinicians in diagnosing patients with… | 2 | 30 | 590 | $70 | $119.3K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 238 | 440 | 610 | $40 | $111.5K |
| 88361 | The lab analyst applies a single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. The lab analyst processes the slides using computer assisted… | 2 | 10 | 2,070 | $50 | $97.9K |
| 81455 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen, such as tumor tissue or bone marrow, for DNA and possibly RNA alterations in 51 or more genes known to… | 4 | 10 | 40 | $600 | $74.3K |
| 88377 | The lab analyst applies a single multiplex in situ hybridization probe stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a… | 3 | 10 | 340 | $70 | $51.9K |
| 88237 | The lab analyst performs a procedure to grow a culture of cells from bone marrow or blood in a neoplastic disorder. | 2 | 10 | 60 | $40 | $32.9K |
| 88184 | The lab analyst performs the technical component of a flow cytometry procedure using a cell surface, cytoplasmic, or nuclear marker to characterize cells and aid clinicians in diagnosing patients… | 2 | 30 | 260 | $20 | $24.4K |
| 88341 | The lab analyst applies an additional single antibody stain on a slide or slides prepared from the same patient specimen as the initial antibody stain, such as tumor tissue. Then a qualified… | 15 | 70 | 160 | $30 | $24.1K |
| 88189 | The clinician, typically a pathologist, interprets flow cytometry results of 16 or more markers. | 2 | 20 | 250 | $30 | $19.4K |
Showing 1–10 of 28
Other providers in the same ZIP code as Neogenomics Laboratories Inc, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.